SCHEMBL4064473

SCHEMBL4064473

CC(F)(CC[C@H](C[C@@H](O)[CH]Cc1ccc(Cl)c(Cl)c1)C(N)=O)C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.34
TMEM97 Q5BJF2 3/20 0.32
KCNH2 Q12809 2/20 0.32
PDPK1 O15530 1/20 0.32
IDO1 P14902 2/20 0.32
PYGL P06737 1/20 0.31
TSHR P16473 1/20 0.31
PNMT P11086 2/20 0.31
TRPV1 Q8NER1 1/20 0.31
CDK8 P49336 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
CCR1 P32246 1/20 0.31
SLC6A2 P23975 2/20 0.31
SLC6A4 P31645 2/20 0.31
SLC6A3 Q01959 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
LMNA P02545 1/20 0.31
HSP90AA1 P07900 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059064 0.85 CCR1 (0.33) CCR1
SCHEMBL4065301 0.85 EPHX1 (0.33) VNN1KCNH2CCR1
SCHEMBL4068827 0.85 EPHX1 (0.33) VNN1KCNH2CCR1
SCHEMBL6167494 0.84 CCR1 (0.40) CCR1
SCHEMBL2675451 0.83 CCR1 (0.42) VNN1CCR1
SCHEMBL4071145 0.83 CCR1 (0.34) CCR1
SCHEMBL4067071 0.82 EPHX1 (0.38) CCR1LMNA
SCHEMBL4064796 0.81 EPHX1 (0.44) VNN1SMN1; SMN2
SCHEMBL4068795 0.80 EPHX1 (0.41) VNN1
SCHEMBL4069920 0.78 CCR1 (0.37) CCR1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 EP disclosed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 VNN1 3540/4885TMEM97 3267/4885KCNH2 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.